Evidence-based·Last reviewed May 31, 2026·How we grade evidence

Chromium Polynicotinate

MineralChromiumBest with a meal

Chromium bound to niacin (vitamin B3), patented as ChromeMate. Marketed as more bioavailable and more 'biologically active' than chromium picolinate, but there is no convincing independent evidence that polynicotinate produces better clinical outcomes than other chromium forms. The general chromium evidence base — modest HbA1c reduction in T2DM, trivial weight-loss effect — applies. The case for polynicotinate over picolinate or chloride is theoretical, not empirical.

Quick decision guide

May help most

Adults who want to try chromium for T2DM glycemic adjunct and prefer to avoid the picolinate ligand (which has had historical concerns about in-vitro chromosomal damage at high doses). The clinical benefit is modest regardless of form.

Common dosing range

200–1,000 µg/day chromium per studies; AI is 35 µg/day (men) and 25 µg/day (women).

When to expect effects

8–12 weeks for HbA1c effect; weight-loss effect is minimal at any timepoint.

Watch out for

Effect sizes for both glycemic and weight outcomes are small and inconsistent. Don't substitute chromium for established diabetes therapy or weight-loss programs. Rare renal/hepatic case reports at high doses.

Evidence snapshot

HbA1c reduction in T2DM (any form)Moderate (~0.3%)
Polynicotinate superiority over picolinateLow (unproven)
Weight lossLow (trivial)
Atypical depression adjunctLow

What is it

Chromium polynicotinate is chromium bound to niacin (vitamin B3). It is marketed as ChromeMate and is one of the most studied chromium supplement forms. The niacin-binding may improve absorption and stability compared to chromium chloride or picolinate.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have type-2 diabetes or prediabetes and want a low-cost adjunct alongside (not replacing) your established regimen, with realistic expectations of ~0.3% HbA1c improvement
You prefer to avoid the picolinate ligand for any reason (historical in-vitro chromosomal-damage concerns)
You want a chromium source bound to niacin and find the theoretical bioavailability argument compelling

Probably skip if…

You're hoping for meaningful weight loss — the chromium effect on weight is trivial (~0.5 kg) and not clinically significant
You believe the marketing that polynicotinate is clearly superior to picolinate — that claim isn't supported by independent clinical trials
You already eat a varied diet including broccoli, whole grains, and meats — typical intake usually meets the AI
You're on insulin or sulfonylureas without checking with your clinician — chromium may compound glucose-lowering
You take levothyroxine — chromium reduces its absorption (separate by 3–4 hours)
You have kidney or liver disease — rare adverse case reports at high doses

Evidence at a glance

Glycemic control in type-2 diabetes

Limited Evidence
Effect
~0.3% mean HbA1c reduction in T2DM trials (any chromium form); polynicotinate-specific data sparse
Best fit
Adults with T2DM or prediabetes who want a low-cost adjunct to established care
Time
8–12 weeks for HbA1c effect

Weight loss / body composition

Mixed Evidence
Effect
−0.50 kg vs placebo (Onakpoya 2013 meta-analysis) — trivial
Best fit
None — better-evidenced weight-loss interventions exist (diet, exercise, GLP-1 agonists)
Time
6–14 weeks of trials — still trivial

Atypical depression (with carbohydrate craving)

Mixed Evidence
Effect
Subgroup signal in atypical depression with carbohydrate craving; not robustly replicated
Best fit
Adults with atypical depression (carbohydrate craving, mood reactivity, weight gain) considering a low-cost trial alongside standard treatment
Time
8 weeks in the available trial

Evidence for 3 uses

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

Glycemic control in type-2 diabetes

Supplement benefit
Limited Evidence

Pooled meta-analyses of chromium supplementation in type-2 diabetes show a modest mean HbA1c reduction of approximately 0.3% (range 0.2–0.6% across analyses), with substantial heterogeneity and low-to-moderate certainty. Most trials used chromium picolinate or yeast-bound chromium; chromium polynicotinate has been tested less. There's no convincing evidence that polynicotinate outperforms other forms for glycemic control. A 0.3% HbA1c drop is real but small — about a third of what a typical diabetes medication achieves and meaningfully less than diet + activity changes. Use as an adjunct, not a substitute, and don't expect dramatic results.

Effect size
~0.3% mean HbA1c reduction in T2DM trials (any chromium form); polynicotinate-specific data sparse
Time to effect
8–12 weeks for HbA1c effect
Best fit
Adults with T2DM or prediabetes who want a low-cost adjunct to established care
Less likely
People without diabetes hoping for blood-sugar normalisation

Bottom line: Modest, real, but small glycemic effect. Won't replace metformin or lifestyle change.

Evidence is mixed

Effect sizes vary substantially across trials; some negative trials exist; chromium polynicotinate has not been studied at scale comparable to picolinate or chromium yeast.

SourceCostello et al., 2019 — Cochrane Database of Systematic Reviews / NIH ODS-cited review· conflicting
SourceCostello et al., 2019 — Cochrane Database of Systematic Reviews / NIH ODS-cited reviewNIH Office of Dietary Supplements — Chromium — Health Professional Fact SheetMSKCC About Herbs — Chromium — Memorial Sloan Kettering Cancer Center

Weight loss / body composition

Supplement benefit
Mixed Evidence

Onakpoya's 2013 meta-analysis of 9 RCTs (n=622) found a pooled weight-loss effect of only −0.50 kg vs placebo over typical 6–14 week trials. The authors described this as 'of uncertain clinical relevance.' The mechanism for chromium-related weight loss is theoretically appetite/carbohydrate-craving reduction; the effect is too small to matter for most people seeking weight loss. Polynicotinate has not been shown to do better than picolinate for this outcome.

Effect size
−0.50 kg vs placebo (Onakpoya 2013 meta-analysis) — trivial
Time to effect
6–14 weeks of trials — still trivial
Best fit
None — better-evidenced weight-loss interventions exist (diet, exercise, GLP-1 agonists)
Less likely
Anyone counting on chromium for meaningful weight loss

Bottom line: Don't take chromium for weight loss. The effect is trivial and there are better-evidenced approaches.

SourceOnakpoya et al., 2013 — Obesity Reviews

Atypical depression (with carbohydrate craving)

Disease adjunct
Mixed Evidence

Docherty 2005 tested chromium picolinate 600 µg/day in 113 patients with atypical depression over 8 weeks. The primary endpoint was not strongly positive, but a subgroup with prominent carbohydrate craving and mood reactivity showed benefit. This finding has not been robustly replicated. Polynicotinate has not been tested for depression. The signal is weak and limited to a specific depression subtype.

Effect size
Subgroup signal in atypical depression with carbohydrate craving; not robustly replicated
Time to effect
8 weeks in the available trial
Best fit
Adults with atypical depression (carbohydrate craving, mood reactivity, weight gain) considering a low-cost trial alongside standard treatment
Less likely
Adults with typical (melancholic) depression — no signal

Bottom line: Weak signal in a narrow depression subtype; nothing in polynicotinate's favour over picolinate for this use.

SourceDocherty et al., 2005 — Journal of Psychiatric Practice

How it works

By binding chromium to niacin, polynicotinate provides chromium in a form that resembles 'biologically active' chromium complexes thought to occur naturally. Animal studies suggest higher tissue chromium accumulation with polynicotinate vs picolinate, though human clinical advantages are debated. Like other chromium forms, polynicotinate is investigated for blood sugar control, insulin sensitivity, and lipid effects, with modest and inconsistent evidence.

How to take it

1. Typical dose
• 200 µg/day is a typical starting dose (and exceeds the 35 µg AI by ~6×) • Trials for glycemic control have used 200–1,000 µg/day; 1,000 µg/day is the upper end • Polynicotinate products often supply 200–500 µg per capsule • Take with a meal (improves absorption and consistency)
2. Higher studied dose
Up to 1,000 µg/day has been used in trials for T2DM glycemic control. There is no formal UL for chromium because adverse effects at supplemental intakes are rare in healthy adults, but rare renal and hepatic case reports exist at high long-term doses. Doses above 1,000 µg/day are not better-evidenced and add risk.
3. Timing
Take with a meal that contains some carbohydrate — chromium's modest insulin-sensitising effects are most relevant in the postprandial period. Time of day is otherwise not important; consistency matters.
4. With food
With food.
5. Split dosing
Single daily dose at 200–500 µg is appropriate. Split into 2 doses if you're at 1,000 µg/day to reduce risk of GI upset, with one dose at the largest carbohydrate meal.
6. How long to try
8–12 weeks minimum to evaluate HbA1c effect; expect modest results. Long-term use (years) at typical doses is generally well-tolerated, but reassess benefit periodically. Discontinue if you don't see HbA1c improvement after 12 weeks.

What to track

HbA1c at 12 weeks if treating T2DM — set ~0.3% reduction as the realistic target
Fasting glucose and hypoglycemia symptoms if you're on insulin or sulfonylureas — chromium can compound glucose-lowering
Body weight if you're tracking — don't expect meaningful change
Levothyroxine dose if you're on thyroid replacement — chromium reduces absorption; separate by 3–4 hours
Rare warning signs: persistent flank pain, unusual fatigue, dark urine (renal/hepatic case reports at high doses)

Bottom line: 200–500 µg/day with food. Realistic expectation: small HbA1c improvement in T2DM; nothing meaningful for weight loss.

5 commercial forms

Compare the main delivery options and what they’re best suited for.

Chromium polynicotinate (ChromeMate)

Niacin-bound

Patented form (ChromeMate) — chromium bound to niacin (vitamin B3). Marketed as more bioavailable and biologically active than picolinate. Animal data support better tissue uptake; independent human clinical-outcome data showing superiority over picolinate is lacking.

Theoretically better bioavailability per animal studies; no clear clinical-outcome advantage over picolinate.

Chromium picolinate

Most-studied

Chromium bound to picolinic acid. The form used in the majority of chromium clinical trials (T2DM, weight loss, atypical depression). Historical concerns about in-vitro chromosomal damage from the picolinate ligand at high doses; FDA reviews have not restricted use.

Best-studied form; performs comparably to other forms in head-to-head trials.

Chromium yeast (Saccharomyces cerevisiae)

Whole-food source

Chromium incorporated into yeast biomass. Used in some early T2DM trials. Often well-tolerated but per-capsule chromium content is variable and lower than chromium-picolinate or polynicotinate products.

Comparable to other forms; lower per-capsule chromium content.

Chromium chloride

Inorganic

Inorganic chromium salt. Poorly absorbed compared to organic forms. Mostly used in clinical-research and parenteral-nutrition formulations.

Lower absorption than organic forms; not the consumer-supplement default.

Chromium GTF (glucose tolerance factor)

Marketing term

'GTF chromium' on labels usually refers to chromium yeast or a niacin-bound chromium complex. The original 'GTF' was a hypothesised natural chromium-niacin-amino-acid complex; modern products use the term loosely as a marketing label.

Variable depending on actual form; marketing label, not a chemical specification.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

mild GI upsetheadacheoccasional dizziness

Serious risks

Who should avoid it

Pregnancy & breastfeeding

Pregnancy AI is 30 µg/day; lactation 45 µg/day. Doses within the AI are safe. Supplementing beyond the AI hasn't been well-studied for pregnancy outcomes. Discuss with your obstetrician if you're using chromium for gestational diabetes — established therapies are preferred.

SourceNIH Office of Dietary Supplements — Chromium — Health Professional Fact Sheet

Bottom line: Generally well-tolerated at 200–500 µg/day. The main practical risks are levothyroxine absorption interference and hypoglycemia with diabetes meds.

Interactions

insulin / sulfonylureas / meglitinides (glyburide, glipizide, repaglinide)Moderate

Chromium may modestly improve insulin sensitivity and compound glucose-lowering effects. Monitor blood glucose; you may need to dose-adjust diabetes medications when adding chromium.

SourceMSKCC About Herbs — Chromium — Memorial Sloan Kettering Cancer Center
levothyroxineModerate

Chromium reduces levothyroxine absorption — separate doses by 3–4 hours, with levothyroxine taken first thing in the morning on an empty stomach and chromium with a later meal.

SourceNIH Office of Dietary Supplements — Chromium — Health Professional Fact Sheet
antacids and proton pump inhibitors (PPIs)Minor

Altered gastric pH can reduce chromium absorption. Practical impact depends on timing and dose; separate by 2 hours when feasible.

SourceMSKCC About Herbs — Chromium — Memorial Sloan Kettering Cancer Center
beta-blockersMinor

Some chromium-form data suggest possible effect on beta-blocker levels; clinical relevance is uncertain. Monitor blood pressure if combined long-term.

SourceMSKCC About Herbs — Chromium — Memorial Sloan Kettering Cancer Center
NSAIDs (aspirin, ibuprofen, naproxen)Minor

May modestly increase chromium absorption. Practical impact is small.

SourceNIH Office of Dietary Supplements — Chromium — Health Professional Fact Sheet
high-dose vitamin CMinor

Vitamin C can enhance chromium absorption from supplements. Not necessarily problematic; just worth noting if you're stacking high doses.

SourceNIH Office of Dietary Supplements — Chromium — Health Professional Fact Sheet

Food sources

Broccoli, cooked

Amount
½ cup (11 µg)
%DV
31%

Grape juice

Amount
1 cup (8 µg)
%DV
23%

Turkey breast, roasted

Amount
3 oz (2 µg)
%DV
6%

Whole-wheat English muffin

Amount
1 muffin (4 µg)
%DV
11%

Potato, mashed

Amount
1 cup (3 µg)
%DV
9%

Garlic, dried

Amount
1 tsp (3 µg)
%DV
9%

Basil, dried

Amount
1 tbsp (2 µg)
%DV
6%

Beef cubes, cooked

Amount
3 oz (2 µg)
%DV
6%

Orange juice

Amount
1 cup (2 µg)
%DV
6%

Apple, unpeeled

Amount
1 medium (1 µg)
%DV
3%

Green beans

Amount
½ cup (1 µg)
%DV
3%

Red wine

Amount
5 oz (1–13 µg, highly variable)
%DV
9%

Choosing a product

What to look for on the label — and what to be skeptical of.

Look for…

Per-capsule elemental chromium dose stated in µg (typically 200, 400, or 500 µg)
ChromeMate label if you specifically want the patented polynicotinate form (otherwise the marketing premium adds cost without independent clinical advantage)
Third-party tested (USP, NSF, ConsumerLab) — verifies elemental chromium content matches label
Single-ingredient capsule if you're tracking chromium intake precisely — combo 'glucose support' products often hide chromium dose in proprietary blends
Plain polynicotinate without added niacin (additional niacin can cause flushing; the polynicotinate-bound niacin is too low-dose to flush)

Be skeptical of…

'Most bioavailable chromium' / '10× more bioavailable than picolinate' marketing — claim is based on animal data and manufacturer-funded studies, not independent human RCTs
'Burns fat' or 'melts belly fat' — chromium's weight-loss effect is trivial (~0.5 kg)
Diabetes-cure or insulin-replacement claims — even with the modest HbA1c benefit, chromium is an adjunct at best
'Detoxifies your body' — chromium doesn't detox anything
Mega-dose products (≥1,500 µg/day) marketed for long-term daily use — no added benefit and isolated renal/hepatic case reports
Combination 'glucose support' products with cinnamon, banaba, gymnema, etc., where chromium dose is undisclosed

Frequently asked questions

Is chromium polynicotinate better than chromium picolinate?⌄

Both are commonly used. Some animal data favor polynicotinate; human clinical differences are small and unclear.

References by claim

Glycemic control in type-2 diabetes

NIH Office of Dietary Supplements — Chromium — Health Professional Fact Sheet (2024) link

Costello et al., 2019 — Cochrane Database of Systematic Reviews / NIH ODS-cited review (2016) link

MSKCC About Herbs — Chromium — Memorial Sloan Kettering Cancer Center (2024) link

Weight loss / body composition

Onakpoya et al., 2013 — Obesity Reviews (2013) link

Atypical depression (with carbohydrate craving)

Docherty et al., 2005 — Journal of Psychiatric Practice (2005) link

Safety

Stearns et al., 1995 (CrPic clastogenicity concern) — FASEB Journal (1995) link

Track Chromium Polynicotinate with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store
Evidence-based·Last reviewed May 31, 2026·Evidence current as of May 31, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.